103 related articles for article (PubMed ID: 21224740)
1. Predictors of patients' perceived need for medication to prevent fracture.
Schousboe JT; Davison ML; Dowd B; Thiede Call K; Johnson P; Kane RL
Med Care; 2011 Mar; 49(3):273-80. PubMed ID: 21224740
[TBL] [Abstract][Full Text] [Related]
2. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
[TBL] [Abstract][Full Text] [Related]
3. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
Rabenda V; Hiligsmann M; Reginster JY
Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
[TBL] [Abstract][Full Text] [Related]
4. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention of osteoporosis: Calcium, Vitamin D and bisphosphonate prescribing following distal radial fracture.
Talbot JC; Elener C; Praveen P; Shaw DL
Injury; 2007 Nov; 38(11):1236-40. PubMed ID: 17572417
[TBL] [Abstract][Full Text] [Related]
6. Secondary prophylaxis of osteoporotic fractures in an orthogeriatric service.
Kenealy H; Paul S; Walker K; Garg A
Australas J Ageing; 2011 Mar; 30(1):41. PubMed ID: 21395941
[No Abstract] [Full Text] [Related]
7. Underdiagnosis and under-treatment of osteoporosis following fragility fracture.
Aboyoussef M; Vierkoetter KR
Hawaii Med J; 2007 Jul; 66(7):185-7. PubMed ID: 17879856
[TBL] [Abstract][Full Text] [Related]
8. Clinical practice. Osteoporosis in men.
Ebeling PR
N Engl J Med; 2008 Apr; 358(14):1474-82. PubMed ID: 18385499
[No Abstract] [Full Text] [Related]
9. How to prevent glucocorticoid-induced osteoporosis.
Dore RK
Cleve Clin J Med; 2010 Aug; 77(8):529-36. PubMed ID: 20682515
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: opportunities for multidisciplinary interventions.
Teschemaker A; Lee E; Xue Z; Wutoh AK
Am J Geriatr Pharmacother; 2008 Dec; 6(5):240-8. PubMed ID: 19161926
[TBL] [Abstract][Full Text] [Related]
11. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
Cotté FE; Fautrel B; De Pouvourville G
Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
[TBL] [Abstract][Full Text] [Related]
12. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
Bilbao J; Pugh A; Aspy CB
J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
[No Abstract] [Full Text] [Related]
13. Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service.
Premaor MO; Pilbrow L; Tonkin C; Adams M; Parker RA; Compston J
QJM; 2010 Jan; 103(1):33-40. PubMed ID: 19864348
[TBL] [Abstract][Full Text] [Related]
14. Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study.
Sale JE; Gignac MA; Hawker G; Frankel L; Beaton D; Bogoch E; Elliot-Gibson V
BMC Musculoskelet Disord; 2011 May; 12():92. PubMed ID: 21554729
[TBL] [Abstract][Full Text] [Related]
15. Approaches to osteoporosis: screening and implementing treatment in clinical practice.
Rawlins S
J Fam Pract; 2009 Jul; 58(7 Suppl Osteoporosis):S39-44. PubMed ID: 19825318
[TBL] [Abstract][Full Text] [Related]
16. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis in men.
Joy M
N Engl J Med; 2008 Aug; 359(8):868; author reply 869. PubMed ID: 18724403
[No Abstract] [Full Text] [Related]
18. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
[TBL] [Abstract][Full Text] [Related]
19. Persistence with bisphosphonate therapy in older people.
Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
[No Abstract] [Full Text] [Related]
20. Who will benefit from antiresorptive treatment (bisphosphonates)?
Papapoulos SE
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
